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A NOVEL APPROACH FOR EX-VIVO EXPANSION (EVE) OF NK CD3-/
CD16/56BRIGHT/DIM SUBSETS EXPRESSING INCREASED INHIBITORY
RECEPTORS FROM CRYOPRESERVED/THAWED/EXPANDED/RECRYO-
PRESERVED/RETHAWED (CTECT) AND CRYOPRESERVED/THAWED/RE-
CRYOPRESERVED/RETHAWED/EXPANDED (CTCTE) UMBILICAL CORD
BLOOD (UCB) USING ANTI-CD3, IL-2, IL-7 AND IL-12 (AB/CY)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Simpson, L.L.1, Kurtzberg,
J.2, Cairo, M.S.1 1. Children’s Hospital of New York-Presbyterian,
Columbia University, New York, NY; 2. Duke University, Durham,
NC
CD56brightdimNK express killer-Ig-like receptors (KIR) and
C-lectin (NKG2), and natural cytoxicity receptors (NCR) involved
with tumor target recognition may play a role in ACI of malig-
nancies (Farag et al, Blood 100:1935, 2002). We compared expan-
sion, maturation and cell survival of CD3-/CD16/56,
CD56bright/dim, KIR inhibitory and C-lectin NK subsets in UCB
aliquots. Non-adherent cells were cultured in SF AIM-V alone or
with anti-CD3 (50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and
IL-12 (10 ng/ml) (AB/CY). The expanded population was analyzed
for expression of NK subsets (CD94, CD16, CD56bright/dim)
and NK receptors (KIR3DL1, KIR2DL1/S1, KIR2DL2 and
NKG2A) by ﬂow cytometry using CD16, CD56, NKBL1,
CD158a, CD158b, CD94 and NKG2A mAbs. Apoptotic markers
were determined by presence of Annexin V and PI. A signiﬁcant
increase in CD16/CD56bright /dim  and CD94/NKG2A ex-
pression was seen in CTECT and CTCTE in AB/CY compared to
AIM-V alone (CD16/56bright/CTECT: 11 1 vs 2.5 .3%, p
.05; CD16/CD56dim: 46  6 vs 27  2%, p  .03; CD16/
56bright/CTCTE: 9  2 vs 2  .2%, p  .05; CD16/CD56dim:
40  2 vs 27  3%, p  .01; CD94/NKG2A: CTECT: 17  3
vs 2  .9%, p  .001; CTCTE: 25  2 vs 8  3%, p  .001).
Signiﬁcant increases were seen in NK KIR receptors expression
(CD56bright/KIR3DL1 and CD56dim/KIR3DL1) when AB/CY
was compared to AIM-V (CTECT: 11  0.7 vs .4  .07%, p 
.0001; 4  0.1 vs 1.5  0.4%, p  .003; CTCTE: 7  2 vs 1  .3
%, p  .05; 8  1 vs 3  .8%, p  .01, respectively), CD56bright/
KIR2DL1/S1 and CD56dim/KIR2DL1/S1 (CTECT: 12  1 vs
3  .4%, p  .004; 41  2 vs 9  1%, p  .0002; CTCTE: 6 
.5 vs 2  .1%, p  .05; 22  8 vs 5  1, p  .01) and CD56bright/
KIR2DL2 and CD56dim/KIR2DL2 (CTECT: 14  .8 vs 2 
.2%, p  .0002 and 29  .9 vs 12  .4%, p  .0001; CTCTE:
14  2 vs 2  .1%, p  .05 and 25  7 vs 6  1%, p  .001,
respectively). To determine if the increase was secondary to in-
creased cell survival, CTECT and CTCTE AB/CY expanded
cultures showed minimal apoptosis compared to SF AIM-V (1.1 
3 vs 6 .5%, p .001; 5 1 vs 11 .6%, p .05). No signiﬁcant
difference between CTECT and CTCTE modalities was seen
except in CD94/NKG2A (p  .05) and CD56bright/KIR2DL2
(p  .05). These data suggest that CD16/CD56bright/dim NK
subsets expressing increased KIR and C-lectin receptors can be
EvE with AB/CY from CTECT or CTCTE UCB for possible use
in ACI for DLI after UCBT. In-vitro functional and in-vivo
xenotransplant animal studies are underway to further examine the
cytolytic activity of these UCB NK subsets.
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EX VIVO EXPANSION OF IMMATURE AND MATURE T CELLS DERIVED
FROM UMBILICAL CORD BLOOD (UCB)
Staba, S.L., Crapnell, K.B., Hall, J.G., Reese, M., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Unrelated umbilical cord blood (UCB) is an effec-
tive source of allogeneic hematopoietic stem cells for transplanta-
tion therapy in patients lacking matched bone marrow donors.
Opportunistic infection is the major cause of mortality post trans-
plant, due in part to the immunologic naivete´ of the UCB T-cells.
We hypothesized that UCB derived immature and mature T-cells
could be expanded ex-vivo, and utilized a patient-derived skin
stromal layer with a supplemental cytokine cocktail to support the
growth of bulk UCB cells. The long term goal is to provide
UCB-derived adoptive immunotherapy in UCBT recipients.
Methods: Patient derived skin ﬁbroblasts were cultured in a media
of IMDM, 10% fetal calf serum and 10% horse serum for 14 days,
then irradiated to 5,000 cGy. Cryopreserved UCB cells were
thawed and cultured on this stromal layer in the same media
supplemented with a cytokine cocktail of interleukin-7 (IL-7) (10
ng/ml), ﬂt-3 ligand (10 ng/ml), and stem cell factor (50 ng/ml).
UCB cells were cultured with cytokines alone and skin alone as
controls. As a 2nd phase, interleukin-2 (IL-2) was added at day 14
for further expansion, with cells cultured for an additional 14 days
thereafter. Cell count, viability, and FACs analysis were per-
formed. Results: Gating on CD3, in cells cultured with both
skin stroma and cytokines mean fold increases of 6 in CD4, 11 in
CD8 and 34 in CD4/CD8 cells were seen. With cytokines
alone, mean fold increases were 3, 4 and 10 respectively. Minimal
expansion occurred with skin alone. With cytokines and IL-2,
mean fold increases were 4 in CD4, 4 in CD8 and 10 in
CD4/CD8 cells. Maximal expansion occurred with skin
stroma, the cytokine cocktail and IL-2, with mean fold increases of
9 in CD4, 11 in CD8 and 53 in CD4/CD8 cells. Results are
summarized in the table below. Conclusions: The expansion of
T-cells from unfractionated, red blood cell depleted, cryopreserved
UCB can be accomplished using a cytokine cocktail of IL-7, Flt 3
ligand and SCF over a patient derived, irradiated skin stromal
layer. Maximal expansion occurs with the addition of IL-2 and was
greatest in the immature CD4/CD8T-cell subset. We hypoth-
esize that this subset of T cells could serve as a target population
for adoptive immunotherapy, however further testing will deter-
mine the optimal cellular target and conditions for ex vivo expan-
sion and immunization. These cells could then be used to augment
immune reconstitution after UCBT.
27
ISOLATION AND FUNCTIONAL INHIBITORY AFFECTS OF SPECIFIC PEP-
TIDES BOUND TO TYPE 2 DENDRITIC CELLS (DC2)
Rosenthal, H.S., Jaye, D.L., Cherry, E., Waller, E.K. Emory Univer-
sity, Atlanta, GA
Introduction: The impact of immunoregulatory type 1 (DC1)
and type 2 (DC2) dendritic cells in allogeneic hematopoetic pro-
genitor cell (HPC) transplantation has increased in interest. We
have shown that greater numbers of DC2s in allogeneic HPC
transplanted grafts has resulted in an increase in post-transplant
relapse and a reduction of graft vs host disease (GVHD). Isolation
of dendritic cell speciﬁc peptides thru phage display technology
provides a method of studying the immunoregulatory affects of
these cells and perhaps engineer grafts with anti-tumor affects.
Method: Random phage peptide libraries were incubated over-
night at 4° C with column enriched peripheral blood DC2 cells.
Unbound phage was removed by washing. FACS sorting of the
Lin-, CD123, HLA-Dr cells, further puriﬁed the DC2 popu-
lation. DC2 bound phage were removed from the cell surface,
eluted and puriﬁed. Three rounds of this phage selection process
(panning) were performed. A portion of the round 2 phage puri-
ﬁcation was incubated with enriched monocytes prior to incuba-
tion with DC2 cells to assist in eliminating phage that recognized
common epitopes on both cell types. Flow cytometry identiﬁed
individual phage clones isolated from plaque assays that were
Table.
Conditions
Mean Fold Expansion
CD4 CD8 CD4/CD8
Skin Alone (n  8) 0 0 0
Cytokines (n  10) 3 4 10
Cytokines  IL-2 (n  5) 4 4 10
Skin  Cytokines (n  10) 6 11 34
Skin  Cytokines  IL-2 (n  5) 9 12 53
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highly DC2 selective. Selective clones were DNA sequenced re-
vealing the random peptide insert. A 1-way MLR was performed
with varying dilution of each ampliﬁed DC2 speciﬁc phage to
demonstrate the cellular affects on allogeneic T-cell proliferation.
Results: Plaque assays from the monocyte adsorbed or non-ad-
sorbed linear random peptide library after the three rounds of
panning revealed two consensus sequences in 76 of the 78 (97%)
isolated clones that were DC2 selective and one sequence found
twice (3%) that was non-DC2 selective. The employed circular
random peptide library revealed no DC2 selective sequences from
15 isolated in clones from the monocyte adsorbed and non-ad-
sorbed plaque assays. Preliminary MLR data shows a 35 % reduc-
tion in allogeneic T-cell proliferation with the DC2 speciﬁc phage
compared to control phage. Conclusions: Data shows that phage
display technology can result in isolating highly speciﬁc DC2
peptides from a library of 10,000 different phage clones. Prelimi-
nary data suggests that binding DC2 speciﬁc peptides may inhibit
the function of these immunoregulatory cells, leading to enhanced
anti-tumor affect of the transplanted donor graft product by shift-
ing it towards an activated Th1 immune response.
GVH/GVL
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TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR
AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE
LEUKEMIA INCREASES THE RISK OF GRAFT-VERSUS-HOST DISEASE
AND DEATH
Ringde´n, O.1, Labopin, M.2, Gorin, N.C.2, Le Blanc, K.1, Rocha, V.3,
Gluckman, E.3, Reiffers, J.4, Arcese, W.5, Vossen, J.M.6, Jouet, J.-P.7,
Cordonnier, C.8, Frassoni, F.9 1. Centre for Allogeneic Stem Cell Trans-
plantation and Division of Clinical Immunology, Huddinge Univ. Hos-
pital, Stockholm, Sweden; 2. Hopital Saint-Antoine and EBMT Data
Center, Institut des Cordeliers, Paris, France; 3. Hopital Saint-Louis,
Paris, France; 4. GRP Hopital de Haut-Leve`que, Pessac, France; 5.
University La Sapienza, Rome, Italy; 6. BMT Centre, Leiden University
Hospital, Leiden, Netherlands; 7. Service des Maladies du Sang, Hospital
Claude Huriez, Lille, France; 8. Hospital Henri Mondor, Creteil,
France; 9. Ospedale San Martino, Genova, Italy
Purpose: Granulocyte colony-stimulating factor (G-CSF) is
given after bone marrow transplantation (BMT) to shorten the
neutropenic phase. Its effects have not been evaluated in a large
patient population. Patients and Methods: We studied 1789 pa-
tients with acute leukaemia receiving BMT and 434 patients re-
ceiving peripheral blood stem cells (PBSC) from HLA-identical
siblings from 1992 to 2002 and reported the ﬁndings to the Eu-
ropean Group for Blood and Marrow Transplantation (EBMT).
Among the BMT and PBSC patients, 501 (28%) and 175 (40%),
respectively, were treated with G-CSF during the ﬁrst 14 days after
the transplant. The outcome variables were entered in a Cox
proportional hazard model. Results: BMT and PBSC patients
treated with G-CSF had a faster engraftment of absolute neutro-
phils 0.5  109/l (p  0.01), but platelet engraftment (50 
109/l) was slower (p  0.001). In the BMT patients, acute graft-
versus-host disease (GVHD) grades II-IV was 50  5% (95%
conﬁdence interval) in the G-CSF group vs. 39  3% in the
controls (relative risk (RR) 1.33, p  0.007, in the multivariate
analysis). The incidence of chronic GVHD was also increased (RR
0.29, p  0.03).
G-CSF was associated with an increase in transplant-related
mortality (TRM) (RR 1.73, p  0.00016), had no effect on relapse,
but reduced the survival (RR 1.7, p  0.0001) and leukaemia-free
survival rates (LFS) (RR 1.55, p  0.0003). No such effects of
G-CSF were seen in patients receiving PBSC. Conclusion: After
BMT, platelet engraftment was delayed, and GVHD and TRM
were increased. Survival and LFS were reduced. This suggests that
G-CSF should not be given shortly after BMT.
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SUBEROYLANILIDE HYDROXAMIC ACID REDUCES ACUTE GRAFT-VER-
SUS-HOST DISEASE AND PRESERVES GRAFT-VERSUS-LEUKEMIA EF-
FECT BY INHIBITING HISTONE DEACETYLATION
Reddy, P.1, Maeda, Y.1, Hotary, K.1, Dinarello, C.A.2, Ferrara, J.L.1 1.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;
2. University of Colorado Medical Center, Denver, CO
Pro-inﬂammatory cytokines and the loss of gastrointestinal tract
integrity contribute to acute graft-versus-host disease (GVHD)
whereas the donor cytotoxic responses are critical for graft-versus-
leukemia (GVL) preservation. Suberoylanilide hydroxamic acid
(SAHA) is an anti-tumor agent that inhibits the activity of histone
deacetylases (HDAC) and reduces the production of proinﬂamma-
tory cytokines. Using a well characterized allogeneic murine BMT
model B6 (H-2b) 3 B6D2F1 (H-2b/d) we studied the effects of
HDAC inhibition by SAHA on acute GVHD. Recipients were
transplanted with 2x10 6 donor T and 5x106 BM cells after13 GY
TBI. Intra-peritoneal injections of 35 mg/kg/day of SAHA from
days 3 to day 7 increased histone H3 acetylation in splenocytes
harvested 7 days after BMT, conﬁrming the inhibition of HDAC
enzymes. SAHA treatment signiﬁcantly reduced the serum levels of
pro-inﬂammatory cytokines such as TNF-a, IL-1	 and IFN-

(P  0.04) in the allogeneic recipients on day 7 after BMT.
Intracytoplasmic staining by ﬂow cytometry and RPA analysis of
the host splenocytes on day 7 conﬁrmed the decrease in the
cytokine protein and mRNA. SAHA signiﬁcantly improved the
survival (P 0.002) and reduced intestinal damage from GVHD of
the allogeneic recipients . However SAHA did not suppress the
donor T cell expansion in vivo and the proliferative and cytotoxic
responses to host antigens in vitro measured 7 and 14 days after
BMT. To test the effect of SAHA on GVL effects, recipients were
injected with lethal doses of P815 (H-2d) tumor cells at the time of
BMT. SAHA treatment resulted in signiﬁcantly improved leuke-
mia-free survival after allogeneic BMT (P  0.05) whereas all the
syngeneic BMT recipients of SAHA died of tumor ruling out
direct anti-tumor effects of SAHA. Furthermore SAHA increased
H3 acetylation in the splenocytes from both the syngeneic and
allogeneic leukemic recipients on day 7, conﬁrming that inhibi-
tion of HDAC enzymes alone is not sufﬁcient for leukemia free
survival in this system. We also tested the effect of SAHA in a
second allogeneic BMT model (BALB/c 3 B6), where it also
signiﬁcantly improved survival (P  0.001) and preserved GVL
effects when recipient mice were injected with lethal doses of EL-4
(H-2b) tumor (P  0.04). We conclude that HDAC inhibition
regulates acute GVHD in these models and suggest that this class
of pharmacologic agents may provide a novel strategy to reduce
GVHD while maintaining the beneﬁcial GVL effects.
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ABROGATION OF THE INTERACTIONS BETWEEN CXCR3 AND ITS LI-
GANDS MIG AND IP-10 REDUCES THE SEVERITY OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Hildebrandt, G.C.1, Corrion, L.C.1, Olkiewicz, K.M.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Chemokines are important mediators in the development of
Idiopathic Pneumonia Syndrome (IPS), a major cause of mortality
after allogeneic (allo) stem cell transplantation (SCT). We hypoth-
esized, that recruitment of donor T cells to the lung is dependent,
at least in part, upon interactions between the chemokines MIG
and IP-10 and their receptor CXCR3. CXCR3 is expressed on
activated T cells; MIG and IP-10 can be induced in various cell
types by IFN
 alone or in combination with TNFa or IL-1ß. We
tested this hypothesis using an established murine SCT model
wherein lethally irradiated bm1 mice receive SCT from either
syngeneic (bm1) or allogeneic (B6Ly5.2) donors. MIG and IP-10
BAL levels were signiﬁcantly elevated in allo recipients compared
to syn controls at weeks 1 (MIG: 162.8  37.6 vs 0; IP-10: 41.1 
4.2 vs 0 pg/ml) and 4 (MIG: 153.5  41.7 vs 21.6  9.0; IP-10:
202.0  61.1 vs 3.8  0.9 pg/ml) and correlated with the inﬁltra-
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